Insider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Sells 1,500 Shares of Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total transaction of $185,625.00. Following the completion of the sale, the chief executive officer now directly owns 440,307 shares of the company’s stock, valued at approximately $54,487,991.25. The trade was a 0.34 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock traded down $5.62 during midday trading on Thursday, hitting $120.82. 1,428,835 shares of the company’s stock were exchanged, compared to its average volume of 746,737. The company has a market cap of $7.34 billion, a P/E ratio of 17.02, a PEG ratio of 1.04 and a beta of 0.44. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The stock has a 50-day moving average price of $132.54 and a two-hundred day moving average price of $122.92. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $148.06.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Fuller & Thaler Asset Management Inc. raised its position in shares of Jazz Pharmaceuticals by 117.4% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company’s stock valued at $115,681,000 after buying an additional 507,234 shares in the last quarter. Darwin Global Management Ltd. bought a new position in Jazz Pharmaceuticals in the fourth quarter valued at $59,668,000. Dimensional Fund Advisors LP raised its position in Jazz Pharmaceuticals by 18.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock valued at $250,619,000 after purchasing an additional 320,724 shares in the last quarter. Ameriprise Financial Inc. raised its position in Jazz Pharmaceuticals by 20.9% during the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock valued at $225,076,000 after purchasing an additional 315,608 shares in the last quarter. Finally, GMT Capital Corp lifted its stake in Jazz Pharmaceuticals by 140.0% during the fourth quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company’s stock worth $62,659,000 after purchasing an additional 296,800 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on JAZZ. Wells Fargo & Company upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $130.00 to $170.00 in a report on Thursday, February 13th. JPMorgan Chase & Co. boosted their price objective on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Needham & Company LLC restated a “buy” rating and issued a $210.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, March 5th. Royal Bank of Canada decreased their price target on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a report on Wednesday, February 26th. Finally, Piper Sandler restated an “overweight” rating and set a $176.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $187.71.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.